Form 4: Amicus Therapeutics Director Lynn Dorsey Bleil Granted New Equity Awards

Amicus Therapeutics, Inc. Director Lynn Dorsey Bleil was granted 20,414 Restricted Stock Units and 74,872 stock options, vesting one year from the grant date of June 5, 2025.

Summary

• Lynn Dorsey Bleil, a Director of Amicus Therapeutics, Inc. (FOLD), was granted equity awards on June 5, 2025.
• The awards include 20,414 Restricted Stock Units (RSUs) and 74,872 stock options.
• The RSUs are equivalent to common stock and will vest in full on the one-year anniversary of the grant date, which is June 5, 2026.
• The stock options have an exercise price of $5.96 and will also vest 100% on the one-year anniversary of the grant date (June 5, 2026), with an expiration date of June 5, 2035.
• Following these transactions, Lynn Dorsey Bleil beneficially owns 113,941 shares of common stock and 74,872 stock options.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but not indicative of significant new positive or negative company performance. It's a standard compensation event.

Positives

• Grant of 20,414 Restricted Stock Units (RSUs) to Director Lynn Dorsey Bleil, aligning her interests with shareholder value.
• Grant of 74,872 stock options with an exercise price of $5.96 to Director Lynn Dorsey Bleil, providing long-term incentives.
• The equity grants represent a routine compensation mechanism for a director, indicating continued engagement and commitment.

Future Outlook

The granted Restricted Stock Units and stock options are subject to a one-year vesting period, indicating that the full benefit of these awards will be realized on June 5, 2026, provided the director remains with the company. The stock options have a long-term expiration date of June 5, 2035, providing a long window for potential exercise.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director, which is a common practice across industries, including the biotechnology and pharmaceutical sectors where Amicus Therapeutics operates. Such grants are standard mechanisms to align director incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options as part of director compensation is a standard practice in the biotechnology and pharmaceutical industries, similar to companies like BioMarin Pharmaceutical Inc. (BMRN) or Sarepta Therapeutics, Inc. (SRPT), which frequently use equity awards to incentivize their leadership.
• The one-year vesting period for these awards is a common structure for annual director grants, ensuring continued commitment.
• The exercise price of $5.96 for the options is likely based on the market price of Amicus Therapeutics (FOLD) common stock on the grant date, a typical approach for compensatory option grants.

Related Party Transactions

• The grant of equity awards to Lynn Dorsey Bleil, a Director of Amicus Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders by tying a portion of her compensation to the company's stock performance. Dilution from the issuance of shares upon vesting/exercise is a minor consideration.

Next Steps

• Vesting of 20,414 Restricted Stock Units on June 5, 2026.
• Vesting of 74,872 stock options on June 5, 2026.
• Potential exercise of stock options by June 5, 2035.

Key Dates

Keywords

Amicus Therapeutics, FOLD, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Lynn Dorsey Bleil